High-Dose Intravenous Vitamin C and Mortality and Organ Dysfunction in Severe Burn Injury: The VICTORY Randomized Clinical Trial.
JAMASep 15, 2026
Christian Stoppe, Aileen Hill, Leopoldo C Cancio et al.
✦ AI-curated · Sources linked
In 30 seconds
The VICTORY trial was a randomized, double-blind, placebo-controlled study assessing high-dose intravenous vitamin C in 238 adults with severe burn injuries. The trial was halted early due to futility, revealing that 28-day mortality was significantly higher in the vitamin C group at 15.0% compared to 7.6% in the placebo group (adjusted RR, 1.96).
Key findings
- 28-day mortality was 15.0% in the vitamin C group vs 7.6% in the placebo group (adjusted RR, 1.96).
- The primary composite outcome occurred in 40.8% of the vitamin C group vs 29.7% in the placebo group (adjusted RR, 1.28).
- Hospital mortality was higher in the vitamin C group at 23.3% compared to 16.1% in the placebo group (adjusted RR, 1.44).
- Time to discharge alive from hospital within 90 days was not improved (adjusted subdistribution hazard ratio, 0.85).
Why it matters
This study highlights the potential risks associated with high-dose intravenous vitamin C in severe burn patients, suggesting that it may not only be ineffective but also harmful, which is critical for clinical decision-making.